ORIGINAL ARTICLE: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

New cases in Pous 2064, HIV = 175, AIDS = 26, Death = 2. HIV rate is very high in Housewives than sex workers in Nepal ! ! ! HIV status in Nepal till 2005: Total Adult=70000, Adult Prevalence (15-49)=0.55%, Number of Women (15-49) LWHA=15,310 (22%), HIV Prevalence rate in IDUs=32.7%, HIV prevalence rate in sex worker=3.8%, HIV prevalence rate in client of SW=2.1%. The latest U.N. report shows that 65 million people have been infected with HIV since it was first identified 25 years ago. Twenty five million people have died of AIDS.

Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.

Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!

You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!

If you have any problems with the registration process or your account login, please contact us.

		xenoMED > News Room > Health News > NEJM
ORIGINAL ARTICLE: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

NEJM The New England Journal of Medicine

(#1 (permalink))

News is Offline

Senior Member

Posts: 673

Thanks: 0

Thanked 33 Times in 33 Posts

Join Date: Sep 2007

ORIGINAL ARTICLE: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer - 02-07-2008, 02:40 PM

This phase 2 trial investigated the efficacy of motesanib diphosphate, an orally active inhibitor of VEGF receptors, in patients with advanced differentiated thyroid cancer. None of the patients had had a response to conventional treatment. No patient had a complete response, but 14% had a partial response, with a median duration of 32 weeks. Motesanib diphosphate is an option for patients with metastatic or locally progressive differentiated thyroid cancer who have not had a response to usual treatment.

More...

« PERSPECTIVE: Health Care Reform in Massachusetts -- Expanding Coverage, Escalating Co | EARLY RELEASE: Guns and Health »

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
John Hopkins University Cancer Updates	basant	Medical Student	2	24-07-2007 08:34 PM
Spiral CT Screening for Lung Cancer Detects Early Curable Disease	Angel	Journal Club	0	25-10-2006 08:41 PM
Can Most Types Of Cancers Be Prevented?	Angel	Medical Breakthrough	1	21-12-2005 07:26 PM

Hosted and Maintained by: